Search research articles
Contact Us
Filters
Showing results (51-60 of 73) with videos related to
Page
of 8
Sort By:
JCO Global Oncology
|
February 14, 2022
Mapping Pediatric Oncology Clinical Trial Collaborative Groups on the Global Stage
Ajay Major, Monica Palese, Ebru Ermis, et al.
Blood Cancer Journal
|
May 22, 2026
Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma
Karan L Chohan, Rina L Welkie, James Godfrey, et al.
American Journal of Hematology
|
February 8, 2022
Persistence of Ad26.COV2.S-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies
Adam J Kanack, Bandana Singh, Gemlyn George, et al.
Scientific Reports
|
July 31, 2025
Factors associated with health-related quality of life and financial toxicity among gynecological cancer patients in Southern Nigeria
Chibuzor F Ogamba, Adedayo Joseph, Ayodeji Kayode Adefemi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 1, 2026
CAR T-Cell Therapy for Cancer: Updates and Challenges for Response Assessment
Dorine de Jong, Jeremy P McGale, Timothy J Robinson, et al.
JCO Oncology Practice
|
January 6, 2022
Impact of COVID-19 on Hematology-Oncology Trainees: A Quantitative and Qualitative Assessment
Urshila Durani, Ajay Major, Ana I Velazquez, et al.
The New England Journal of Medicine
|
July 6, 2017
PD-1 Blockade in Mediastinal Gray-Zone Lymphoma
Christopher Melani, Ajay Major, Jeffrey Schowinsky, et al.
Polish Archives of Internal Medicine
|
May 15, 2024
Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone
Tadeusz Kubicki, Krzysztof Jamroziak, Paweł Robak, et al.
Blood Cancer Journal
|
March 27, 2025
Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers
Timothy J Voorhees, Eric M McLaughlin, Pallawi Torka, et al.
Blood Advances
|
June 9, 2026
Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab
Allison M Bock, Lei Feng, Ayushi Chauhan, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 73) with videos related to
Sort By:
Page
of 8
JCO Global Oncology
|
February 14, 2022
Mapping Pediatric Oncology Clinical Trial Collaborative Groups on the Global Stage
Ajay Major, Monica Palese, Ebru Ermis, et al.
Blood Cancer Journal
|
May 22, 2026
Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma
Karan L Chohan, Rina L Welkie, James Godfrey, et al.
American Journal of Hematology
|
February 8, 2022
Persistence of Ad26.COV2.S-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies
Adam J Kanack, Bandana Singh, Gemlyn George, et al.
Scientific Reports
|
July 31, 2025
Factors associated with health-related quality of life and financial toxicity among gynecological cancer patients in Southern Nigeria
Chibuzor F Ogamba, Adedayo Joseph, Ayodeji Kayode Adefemi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 1, 2026
CAR T-Cell Therapy for Cancer: Updates and Challenges for Response Assessment
Dorine de Jong, Jeremy P McGale, Timothy J Robinson, et al.
JCO Oncology Practice
|
January 6, 2022
Impact of COVID-19 on Hematology-Oncology Trainees: A Quantitative and Qualitative Assessment
Urshila Durani, Ajay Major, Ana I Velazquez, et al.
The New England Journal of Medicine
|
July 6, 2017
PD-1 Blockade in Mediastinal Gray-Zone Lymphoma
Christopher Melani, Ajay Major, Jeffrey Schowinsky, et al.
Polish Archives of Internal Medicine
|
May 15, 2024
Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone
Tadeusz Kubicki, Krzysztof Jamroziak, Paweł Robak, et al.
Blood Cancer Journal
|
March 27, 2025
Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers
Timothy J Voorhees, Eric M McLaughlin, Pallawi Torka, et al.
Blood Advances
|
June 9, 2026
Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab
Allison M Bock, Lei Feng, Ayushi Chauhan, et al.
Page
of 8